Browsing Category
Featured Articles
Sensei Biotherapeutics Reports New Data from Phase 1 Clinical Trial of SNS-301
Sensei Biotherapeutics announced the publication of data from the company’s multi-center Phase 1 clinical trial to assess safety and immunogenicity of SNS-301 (formerly PAN-301) in…
Read More...
Read More...
Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug…
Daiichi Sankyo Company announced the launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development (hereafter, the consortium) to research and discover drugs for…
Read More...
Read More...
FDA expedites review of Novartis drug Promacta for first-line severe aplastic anemia (SAA)
Novartis announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta…
Read More...
Read More...
MIT team develops single-injection vaccine for the polio virus
A new nanoparticle vaccine developed by MIT researchers could assist efforts to eradicate polio worldwide. The vaccine, which delivers multiple doses in just one injection, could make…
Read More...
Read More...
Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment
Amgen announced a groundbreaking collaboration with the National Cancer Institute(NCI), the Federal Communications Commission (FCC) Connect2Health Task Force, the University of Kentucky…
Read More...
Read More...
FDA to review Zynquista (sotagliflozin) as potential treatment for type 1 diabetes
The U.S. Food and Drug Administration (FDA) has accepted Sanofi's regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to…
Read More...
Read More...
LYRICA (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint
Pfizer announced positive top-line results of a Phase 3 study examining the use of LYRICA (pregabalin) Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric…
Read More...
Read More...
Novartis and Amgen announce FDA approval of Aimovig (erenumab-aooe)
Novartis announced that the US Food and Drug Administration (FDA) has approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic…
Read More...
Read More...
Emulate and AstraZeneca Form Strategic Agreement to Work Side-by-Side on Organs-on-Chips Technology
Emulate, Inc. has formed a collaborative partnership with AstraZeneca’s Innovative Medicines and Early Development (IMED) Biotech Unit to embed its Organs-on-Chips technology within the…
Read More...
Read More...
Lilly’s Galcanezumab Meets Primary Endpoint in Phase 3 Study
Eli Lilly and Company announced that galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster headache, demonstrating statistically significant…
Read More...
Read More...
Cambrex Completes Pilot Plant Expansion at its High Point, NC Facility
Cambrex Corporation announced that it has completed a pilot plant expansion at its High Point, NC facility with the installation and commissioning of a fourth reactor suite, increasing…
Read More...
Read More...
FDA seeks permanent injunctions against two stem cell clinics
The U.S. Food and Drug Administration, in two complaints filed in federal court, is seeking permanent injunctions to stop two stem cell clinics from marketing stem cell products without…
Read More...
Read More...
Scientists identify cause of resistance to breakthrough breast and ovarian cancer drug
Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors.
The study findings could help…
Read More...
Read More...
Lodo Therapeutics Corporation Forms Multi-Target Strategic Collaboration with Genentech
Lodo Therapeutics Corporation, a drug discovery and development company focused on identifying and producing unique, bioactive natural products directly from the microbial DNA sequence…
Read More...
Read More...
Proposed Acquisition of Shire plc by Takeda
Takeda Pharmaceutical Company Limited and Shire plc announced that they have reached agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire…
Read More...
Read More...
Sylentis Announces the Clinical Results of Tivanisiran for the Treatment of Dry Eye Syndrome
Sylentis, Pharmaceutical Company belonging to the PharmaMar Group, has presented results from the clinical studies carried out with tivanisiran for the treatment of dry eye syndrome and…
Read More...
Read More...
MenoGeniX Awarded NIH Grant to Fund Phase Ib/IIa Clinical Trial
MenoGeniX announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant for…
Read More...
Read More...
Ferring Signs Global Agreement to Commercialise Novel Gene Therapy for Bladder Cancer Patients
Ferring Pharmaceuticals announced the signing of an agreement giving the company the option to secure global commercialisation rights to nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3), a…
Read More...
Read More...
Novartis receives FDA approval of Tafinlar + Mekinist for adjuvant treatment of BRAF V600-mutant…
Novartis announced that the US Food and Drug Administration (FDA) has approved Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of patients…
Read More...
Read More...
Merck KGaA, Darmstadt, Germany to Develop Abituzumab in Metastatic Colorectal Cancer with SFJ…
Merck KGaA, Darmstadt, Germany announced a development agreement for investigational molecule abituzumab with SFJ Pharmaceuticals Group (SFJ), a US-based company focused on increasing…
Read More...
Read More...